148 related articles for article (PubMed ID: 10811493)
1. Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument.
Tropé C; Kaern J; Hogberg T; Abeler V; Hagen B; Kristensen G; Onsrud M; Pettersen E; Rosenberg P; Sandvei R; Sundfor K; Vergote I
Ann Oncol; 2000 Mar; 11(3):281-8. PubMed ID: 10811493
[TBL] [Abstract][Full Text] [Related]
2. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
[TBL] [Abstract][Full Text] [Related]
3. Improved 5-year disease-free survival for FIGO stage I epithelial ovarian cancer patients without tumor rupture during surgery.
Paulsen T; Kærn J; Tropé C
Gynecol Oncol; 2011 Jul; 122(1):83-8. PubMed ID: 21435701
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: a single institution experience.
Bamias A; Karadimou A; Soupos N; Sotiropoulou M; Zagouri F; Haidopoulos D; Thomakos N; Rodolakis A; Antsaklis A; Dimopoulos MA
Gynecol Oncol; 2011 Oct; 123(1):37-42. PubMed ID: 21764430
[TBL] [Abstract][Full Text] [Related]
5. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
6. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.
Trimbos JB; Parmar M; Vergote I; Guthrie D; Bolis G; Colombo N; Vermorken JB; Torri V; Mangioni C; Pecorelli S; Lissoni A; Swart AM; ;
J Natl Cancer Inst; 2003 Jan; 95(2):105-12. PubMed ID: 12529343
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of DNA ploidy in patients with stage II and stage III colon carcinoma: a prospective flow cytometric study.
Lanza G; Gafà R; Santini A; Maestri I; Dubini A; Gilli G; Cavazzini L
Cancer; 1998 Jan; 82(1):49-59. PubMed ID: 9428479
[TBL] [Abstract][Full Text] [Related]
8. Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer.
Kristensen GB; Kildal W; Abeler VM; Kaern J; Vergote I; Tropé CG; Danielsen HE
Ann Oncol; 2003 Oct; 14(10):1494-500. PubMed ID: 14504048
[TBL] [Abstract][Full Text] [Related]
9. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer.
Colombo N; Guthrie D; Chiari S; Parmar M; Qian W; Swart AM; Torri V; Williams C; Lissoni A; Bonazzi C;
J Natl Cancer Inst; 2003 Jan; 95(2):125-32. PubMed ID: 12529345
[TBL] [Abstract][Full Text] [Related]
10. [DNA ploidy and results of first line chemotherapy in ovarian cancer patients].
Milczek T; Klasa-Mazurkiewicz D; Emerich J; Debniak J
Ginekol Pol; 2006 Aug; 77(8):589-96. PubMed ID: 17076189
[TBL] [Abstract][Full Text] [Related]
11. [DNA ploidy in epithelial ovarian cancer--an independent prognostic factor].
Tropé CG; Abeler V; Baekelandt M; Kaern J
Tidsskr Nor Laegeforen; 2000 Jan; 120(1):43-9. PubMed ID: 10815478
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.
Winter-Roach BA; Kitchener HC; Dickinson HO
Cochrane Database Syst Rev; 2009 Jan; (1):CD004706. PubMed ID: 19160239
[TBL] [Abstract][Full Text] [Related]
13. Outcome of patients with early ovarian cancer undergoing three courses of adjuvant chemotherapy following complete surgical staging.
Shimada M; Kigawa J; Kanamori Y; Itamochi H; Oishi T; Minagawa Y; Ishihara K; Takeuchi Y; Okada M; Terakawa N
Int J Gynecol Cancer; 2005; 15(4):601-5. PubMed ID: 16014112
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic significance of tumor cell ploidy in advanced ovarian carcinoma].
Novik VI; Gevorkian VA; Maksimov SIa
Vopr Onkol; 2006; 52(1):54-8. PubMed ID: 16715704
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy with carboplatin and taxane compared with single drug carboplatin in early stage epithelial ovarian carcinoma.
Skírnisdóttir I; Lindborg K; Sorbe B
Oncol Rep; 2007 Nov; 18(5):1249-56. PubMed ID: 17914581
[TBL] [Abstract][Full Text] [Related]
16. Multivariate analysis of the prognostic significance of DNA-ploidy and S-phase fraction in ovarian cancer determined by flow cytometry following detection of cytokeratin-labeled tumor cells.
Kimmig R; Wimberger P; Hillemanns P; Kapsner T; Caspari C; Hepp H
Gynecol Oncol; 2002 Jan; 84(1):21-31. PubMed ID: 11748971
[TBL] [Abstract][Full Text] [Related]
17. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G
Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208
[TBL] [Abstract][Full Text] [Related]
18. Survival and prognostic factors in early-stage epithelial ovarian carcinoma treated with taxane-based adjuvant chemotherapy.
Skírnisdóttir I; Sorbe B
Int J Gynecol Cancer; 2007; 17(6):1231-7. PubMed ID: 17425681
[TBL] [Abstract][Full Text] [Related]
19. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
20. The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer.
van Baal JOAM; Van de Vijver KK; Algera MD; van der Aa MA; Sonke GS; van Driel WJ; Kenter GG; Amant FC; Lok CAR
Gynecol Oncol; 2019 Jun; 153(3):562-567. PubMed ID: 30948193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
